Generation Bio Q2 2025 Earnings Report

Generation Bio EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.28
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Generation Bio Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $2.51 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Generation Bio Announcement Details

• Quarter: Q2 2025
• Date: 8/6/2025
• Time: Before Market Opens
• Conference Call Date: Wednesday, August 6, 2025
• Conference Call Time: 4:00PM ET

Generation Bio (NASDAQ:GBIO) (NASDAQ: GBIO) is a clinical-stage biotechnology company focused on the development of non-viral, persistent gene therapies aimed at treating rare and prevalent diseases. Utilizing its proprietary GeneVector platform, the company engineers synthetic DNA payloads encapsulated in lipid nanoparticles to achieve safe, durable expression of therapeutic proteins. This platform is designed to overcome limitations of traditional viral vectors by offering controlled gene expression, reduced immunogenicity and scalable manufacturing processes.

The company’s pipeline includes multiple preclinical and early clinical programs targeting genetic disorders of the liver, central nervous system and other organ systems. Generation Bio has announced lead programs in metabolic and hematologic diseases, with plans to expand into indications such as rare enzyme deficiencies and neurological conditions. The company leverages its integrated research, development and manufacturing capabilities to accelerate candidate selection and produce clinical-grade material in-house.

Founded in 2020 and headquartered in Cambridge, Massachusetts, Generation Bio was formed through the merger of 4D Molecular Therapeutics’ non-viral gene therapy platform and Agilis Biotherapeutics’ proprietary vectors. The company maintains key research collaborations and academic partnerships across the United States and Europe, positioning it to advance global clinical development. Its facilities in Greater Boston house specialized teams in vector engineering, analytical development and process scale-up.

Generation Bio’s leadership team is led by Chief Executive Officer John Evans, who brings extensive experience from previous roles at Arvinas and Pfizer. The executive team includes seasoned biopharmaceutical professionals specializing in gene therapy, regulatory affairs and operations. The company’s board of directors comprises industry veterans focused on driving innovation and strategic growth in the emerging field of non-viral gene therapy.